Dr. Cyrus D. Mozayeni is co-founder, President and CEO of Vedere Bio and Entrepreneur-in-Residence at Atlas Venture. Prior to Vedere, he was co-founder of CODA Biotherapeutics, and Oncorus (NASDAQ: ONCR) where he served as President and CBO. Prior to Oncorus, Cyrus served as VP and global head of business development and alliance management at bluebird bio (NASDAQ: BLUE), where his efforts led to a clinical-stage CAR T-cell program (ABECMA®, idecabtagene vicleucel) in collaboration with Celgene, and a successful IPO. Cyrus earned his Sc.B. in neuroscience from Brown University, his M.D. from the University of Virginia School of Medicine and his MBA from the Kellogg School of Management at Northwestern University. He is a licensed physician, and a Fellow of the Academy of Wilderness Medicine.

Mark Gaffney brings over 20 years’ experience to us and serves as our Chief Operating Officer at Vedere Bio II. He served as Chief Business Officer at Vedere Bio, which included a leading role in its acquisition by Novartis. Prior to his time with the Vedere companies, he led corporate development at Cyclerion Therapeutics, and over a ten-year career with Ironwood Pharmaceuticals, he led the corporate legal and business development functions. Mark started his legal career at Ropes & Gray, and prior to becoming a lawyer, spent five years serving in the United States Air Force. Mark holds a bachelor’s degree in mechanical engineering from the University of Pennsylvania and a law degree from Boston University.

Dr. Karen Guerin is the Senior Director of Virology at Vedere Bio. Prior to joining Vedere, she was an associate director at Addgene, where she focused on AAV production and quality control. She also served as a project team leader and research investigator in gene therapy at the Novartis Institutes for BioMedical Research and was a Research Fellow at Children’s Hospital Boston. Karen holds a B.Sc in neurosciences from the University of Toulouse, an M.Sc in neurosciences and neuropharmacology from the University of Bordeaux, and a Ph.D. in vision science and molecular biology from the University of California, Berkeley.

Daniel Zimmer is Senior Director, Program Lead at Vedere Bio. Prior to joining Vedere, he was a Senior Principal Investigator at Cyclerion, where he led the soluble guanylate cyclase stimulator discovery program, developed and executed pharmacology strategy, and contributed to clinical development of the oral soluble guanylate cyclase stimulators praliciguat and olinciguat. Prior to Cyclerion, he was a Principal Investigator at Ironwood Pharmaceuticals where he led multiple discovery programs. He holds S.B. degrees in biology and chemistry from MIT and a Ph.D. in Molecular Biophysics and Biochemistry from Yale University.